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Wilms tumor (WT) blastema retains gene expression profiles characteristic of the multipotent nephron progenitor
pool, or cap mesenchyme (CM), in the developing kidney. As a result, WT blastema and the CM are believed to
represent contextual analogues of one another. Sine oculis homeobox 2 (SIX2) is a transcription factor expressed
specifically in the CM, provides a critical mechanism for CM self-renewal, and remains persistently active in WT
blastema, although its purpose in this childhood malignancy remains unclear. We hypothesized that SIX2,
analogous to its function in development, confers a survival pathway to blastema, the putative WT stem cell. To
test its functional significance in WT biology, wild-type SIX2 was overexpressed in the human WT cell line, WiT49.
After validating this model, SIX2 effects on anchorage-independent growth, proliferation, invasiveness, canonical
WNT pathway signaling, and gene expression of specific WNT pathway participants were evaluated. Relative to
controls, WiT49 cells overexpressing SIX2 showed significantly enhanced anchorage-independent growth and
early-passage proliferation representing surrogates of cell survival. Interestingly, overexpression of SIX2 generally
repressed TCF/LEF-dependent canonical WNT signaling, which activates and coordinates both differentiation and
stem pathways, but significantly heightened canonical WNT signaling through the survivin promoter, a mechanism
that exclusively maintains the stem state. In summary, when overexpressed in a human WT cell line, SIX2
enhances cell survival and appears to shift the balance in WNT/β-catenin signaling away from a differentiation path
and toward a stem cell survival path.
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Wilms tumor (WT), the most common childhood kidney cancer,
retains gene expression profiles and histologic elements characteristic
of the embryonic kidney and so is classified among embryonal tumors
[1–3]. Typically, WTs show a triphasic pattern of cellular features,
comprised principally of 1) blastema, its putative cancer stem cell and
the malignant analogue of nephron progenitors, 2) epithelia, which
appears more differentiated as primitive tubules and glomeruli but
lacks physiologic function and tissue architecture, and 3) stroma,
which consists mostly of connective tissue fibroblasts but can show
smooth or skeletal muscle, and even cartilaginous, differentiation
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after neoadjuvant therapy, represents a histologic marker of treatment
resistance and has been shown to portend a worse prognosis [6,7].
The 2013 Children’s Oncology Group blueprint for renal tumors
therefore challenges investigators to identify the mechanisms that
maintain blastema interminably and confer treatment resistance to
WT as targets for more efficacious drugs, answers to which likely rest
in the mysteries of cancer stem cell self-renewal and evasion of
standard therapies [8].
Sine oculis homeobox 2 (SIX2) gene encodes a transcription factor
that provides a necessary self-renewal mechanism to nephron
progenitors residing within the cap mesenchyme (CM) of the
embryonic kidney and that protects against canonical WNT pathway
signals directing epithelial differentiation [9–11]. Interestingly,
coordination of asymmetric stem cell division in the developing
kidney, which spawns one daughter cell fated to become nephronic
epithelia and the other to remain in the stem state, depends in part on
integrity and balance of canonical WNT signaling. More specifically,
this β-catenin–dependent cell fate decision, either to differentiate or
to remain stem, relies on its interaction with two co-activators,
CREB-binding protein (CBP), which directly promotes stemness, or
p300, which directs epithelial conversion [12–14]. If the balance in
this tightly regulated binary branch point shifts to a greater symmetric
course of cell division, whereby two daughter stem cells are spawned, a
state of interminable self-perpetuation is created. CBP/β-catenin–
dependent symmetric cell division, which sets up a perpetual loop,
has been proposed as a self-maintenance mechanism of the cancer
stem cell [15]. How SIX2 and β-catenin interact in the highly
regulated coordination of CM asymmetric cell division is incom-
pletely understood; moreover, how this balance shifts to symmetric
cell division in the cancer stem cell remains more elusive yet
represents a candidate target of new therapies [16–18].
To coordinate the critical balance between maintaining a sufficient
nephron progenitor pool while simultaneously spawning committed
epithelial cells within the CMof themurine embryonic kidney, SIX2 and
β-catenin have been shown to share regulatory gene networks, and a tight
interplay has been observed between SIX2 and Wnt9b [11,19].
Curiously, both SIX2 and β-catenin are broadly activated in WT,
which represents an ideal paradigm to study self-renewal of an embryonal
cancer stem cell and its potential for epithelial conversion, given the
typical appearance of WT blastema immediately adjacent to or
surrounding a variety of epithelial structures [20–22]. Although much
has been revealed regarding the function of SIX2 and canonical WNT
signaling in the coordinated process of nephron development, insufficient
evidence has been uncovered regarding these transcriptional regulators in
blastema self-renewal and maintenance of the WT cancer stem cell.
Analogous to its functional significance in the CM, we hypothesized
therefore that exuberant SIX2 expression confers a survival mechanism to
WT and preferentially drives β-catenin toward the CBP-dependent arm
of the canonical WNT pathway to maintain the stem state. These studies
were designed to test SIX2 as a survival mechanism and a modifier of the
canonical WNT pathway in the WT context.
Methods
SIX2 Cellular Distribution in WT
WT clinical specimens. To evaluate SIX2 as a marker of the
putative WT stem cell, or blastema, we conducted a comprehensive
immunohistochemical (IHC) analysis of its cellular distribution inrelation to neural cell adhesion molecule (NCAM, a cell surface
marker of the WT stem cell) [23,24]. Because SIX2 provides self-
renewal to the CM, we also examined SIX2 as a marker of
proliferation by evaluating its association with proliferating cell
nuclear antigen (PCNA, a marker of proliferating cells) expression
across a large sampling of WT specimens. Briefly, using formalin-
fixed paraffin-embedded renal tumor and adjacent kidney specimens
collected prospectively and archived in our Institutional Review
Board (IRB)-approved laboratory embryonal tumor repository, we
created three tissue microarrays (TMA) comprised of 223 total
punches (~1 mm in diameter each). Two hundred and fourteen of
these punches were derived from 43 consecutive childhood renal
tumors (41 WTs, 1 clear cell sarcoma, and 1 mesoblastic nephroma),
and 9 punches originated from 9 discarded human fetal kidney
specimens acquired from therapeutic abortuses. To ensure the highest
punch quality and an adequate sampling of a given kidney tumor
specimen, multiple punches were selected and taken from different
blocks having histologic regions of interest. Serial 5-μm sections of
these three TMAs were included for the IHC analysis, which was
concentrated on the 41 WT specimens (39 favorable and 2
unfavorable histology).
Immunohistochemistry. Using our previously described protocol
for peroxidase-based IHC analysis, serial sections of the three TMAs
were probed, respectively, for SIX2, NCAM, and PCNA [21]. Briefly,
the paraffin blocks containing each TMA were cut in 5-μm sections,
were subjected to heat-induced epitope retrieval in 10 mM citrate
buffer, and were incubated in affinity-purified rabbit anti-SIX2 (1:20
dilution; US Biological Corp, Marblehead, MA), mouse anti-NCAM
(1:100 dilution; Cell Signaling Technology, Danvers, MA), or mouse
anti-PCNA (1:100 dilution; Santa Cruz Biotechnology, Santa Cruz,
CA) antibodies overnight at 4°C. Anti-rabbit or anti-mouse labeled
HRP polymer was applied to tissue sections at room temperature for
30 minutes, and antigens were visualized with a DAKO Envision kit
(DakoCytomation, Carpinteria, CA). Additional sections of whole
WT specimens were incubated with affinity-purified rabbit anti-
CITED1 antibody (1:50; Lab Vision/Neomarkers, Fremont, CA) and
developed also using the DAKO Envision kit, as described [20].
Immunofluorescence to Label the WT Stem Cell
In vivo immunofluorescence. To determine the spatial distribu-
tion of blastema (i.e., the putative WT stem cell) and more
differentiated epithelial structures and patterns of protein co-
expression, human WT was co-labeled with rabbit anti-SIX2
(1:1000) and mouse anti-NCAM (1:1000) antibodies. Importantly,
NCAM has been shown recently to label both nephron progenitors
in the embryonic kidney and a putativeWT stem cell [24–27]. Given
that SIX2 is a fundamental marker of nephron progenitors in the CM
and WT blastema, we questioned what overlap it and NCAM would
show in this malignant context; we hypothesized that SIX2+/
NCAM+ would co-label the most undifferentiated WT blastema.
The immunofluorescence protocol followed for this co-labeling has
been described elsewhere, but briefly, after antigen retrieval and
overnight incubation with these two primary antibodies, DAKO
Envision (DakoCytomation) anti-rabbit HRP polymer and tyramide
signal amplification (PerkinElmer, Waltham, MA) with the
fluorescein isothiocyanate fluorophore (SIX2 labels green) were
added to the slides for 10 minutes [20]. After quenching and
washing, DAKO Envision anti-mouse HRP polymer and tyramide
signal amplification with the Cy3 fluorophore (NCAM labels red)
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with 4′,6-diamidino-2-phenylindole,dihydrochloride (DAPI)
(1:50,000; Invitrogen, Carlsbad, CA), which labels all nuclei blue.
Model of SIX2 Overexpression in WT
WT cell lines. To mimic the observed overexpression of SIX2 in
clinicalWT specimens, the humanWT cell line,WiT49, was cultured as
described and then transfected with the pcDNA3.1 plasmid containing
the Venus green fluorescent protein (vGFP) gene only (control cell line) or
containing both the vGFP and wild-type SIX2 genes (experimental cell
line) [28]. This latter transgene was designed uniquely to produce a
vGFP-2A-SIX2 protein, in which the intervening 19 amino acid 2A
peptide is cleaved immediately after synthesis, thereby liberating the GFP
marker from the amino terminus of SIX2 and eliminating any physical
constraints of this epitope on transcriptional function [29,30]. Briefly,
separate six-well plates of WiT49 cells grown to 80% confluence were
transfected with either transgene using the XtremeGene Transfection
System according to the manufacturer’s protocol (Roche, Indianapolis,
IN) and using 2μg ofDNA and 6μl of transfection reagent in a 1:3 ratio.
The neomycin analog, G418, was added subsequently at a concentration
of 1 mg/ml to select the successfully transfected cells, as the pcDNA3.1
plasmid contains a neomycin resistance cassette. After 5 weeks of G418
selection, inducing stable integration of the transgenes, both theWiT49-
GFP-2A-SIX2 and WiT49-GFP cell lines were flow sorted (FACS) for
viability and the vGFP signal to enrich a population of high-expressing,
GFP-positive cells in each line. Specifically, five million cells were stained
with 7-AAD (BDBiosciences, San Jose, CA) for 20minutes at 4°C. After
washing with 1× phosphate-buffered saline (PBS) containing 2% FBS,
cells were sorted in the Vanderbilt Flow Cytometry Shared Resource for
viability and high expression of vGFP. Cells were collected in medium
containing antibiotics and were placed immediately in culture conditions
for expansion. All validation and functional assays outlined below were
performed using samples from flow-sorted populations of high GFP-
expressing cells.
Model Validation Assays
In vitro immunofluorescence. To validate expression of both
transgenes in the WiT49 cells using detection of vGFP as the surrogate
marker, glass coverslips were coated with 50 μg/ml poly-D-Lysine for 1
hour at room temperature and rinsed two times with 1× PBS. Cells
from the respective lines were plated onto coverslips and, after reaching
80% confluency, were fixed with 4% paraformaldehyde in PBS at 37°C
for 30 minutes. Cells were washed twice with 1× PBS, and coverslips
were applied with fluorescent mounting media. Images were captured
on a Zeiss Axioflor fluorescent microscope.
Western blot. To validate further the integrity of transgene
expression in both cell lines, and specifically to quantitate the differences
in SIX2 expression between control and experimentalWiT49 cell lines,
total protein was extracted from whole-cell lysates, as described [20].
Equal concentrations of protein from passages 2, 3, and 4 of WiT49-
GFP-2A-SIX2 and WiT49-GFP cells were separated on 10% bis-Tris
sodium dodecyl sulfate–polyacrylamide gel electrophoresis gels; protein
samples extracted from wild-type WiT49 cells (SIX2 protein not
detected typically at standard loading concentrations) and a humanWT
specimen that expresses abundant SIX2 served as controls. After protein
separation and transfer, cellulose blots were probed using anti-SIX2
primary antibody (1:1000; US Biological Corp) overnight at 4°C. Blots
were washed thrice and then probed with an anti-rabbit IgG secondary
antibody (1:5000; Jackson ImmunoResearch,WestGrove, PA) at roomtemperature for 1 hour. SIX2 bands were visualized using Pierce ECL
Western Blotting Substrate (Thermo Scientific, Waltham, MA). The
same protocol was followed to detect vGFP expression (Venus GFP
primary antibody, 1:3000; Aves and an anti-chicken IgY secondary
antibody, 1:5000; Jackson ImmunoResearch). Both the SIX2 and
vGFP blots were stripped and reprobed for β-actin (primary antibody,
1:5000; Sigma, St. Louis, MO, and an anti-mouse IgG secondary
antibody at 1:3000, KPL, Gaithersburg, MD).
Functional Assays
Soft agar tumorigenesis assay. To measure SIX2 effects on
anchorage-independent growth of WiT49 cells, the bottom agar was
prepared with 10 ml of 1.6% agar (0.72 g of SeaPlaque agar, 45 ml of
sterile ddH2O), 1 ml of FBS, 0.2 ml of penicillin/streptomycin, and 8.8
ml of Dulbecco's modified Eagle's medium (DMEM) [28]; 1.5 ml of
bottom agarmix was added to eachwell of a six-well plate and allowed to
solidify for 1 hour at room temperature. The top agar layer was prepared
with 5 ml of 1.6% agar, 1 ml of FBS, 0.2 ml of penicillin/streptomycin,
and 13.8 ml of DMEM. Three milliliters of top agar was added to
separate conical tubes, followed by the addition of WiT49-GFP-2A-
SIX2 cells or WiT49-GFP cells to each tube; 0.75 ml of top agar,
containing 12,000 cells per well (n = 5 technical replicates; n = 3
biologic replicates—passages 2, 3, and 5), was added to each well of the
six-well plate. The agar was allowed to solidify for 30 minutes at room
temperature and was placed in a 37°C incubator with 5% CO2 for 3
weeks. The plates were read with a GelCount instrument (Oxford
Optronix,Oxfordshire, UnitedKingdom), housedwithin the Epithelial
Biology Shared Resource of Vanderbilt University Medical Center, to
count colony numbers and to measure colony diameter.
Cellular proliferation. To determine SIX2 effects on WT cellular
proliferation, the CellTiter 96 non-radioactive kit was used (Promega,
Madison,WI), as described [28]. Briefly, 5000WiT49-GFP-2A-SIX2 cells
orWiT49-GFP cells were plated onto a 96-well flat-bottom plate in media
containing 0.2% FBS. Cells were grown for 24, 48, or 72 hours, and 15 μl
of dye reagent was added to each well according to the manufacturer’s
instructions. After 4 hours of incubation with the dye reagent, 100 μl of
stop solution was added. The plates were read in a SpectraMax
spectrophotometer (Molecular Devices, Sunnyvale, CA). Three biologic
replicates (passages 2, 3, and 5; n = 4 technical replicates per passage) of
WiT49-GFP-2A-SIX2 cells and WiT49-GFP cells were analyzed.
Invasion. To assay effects of SIX2 onWT invasiveness, the QCM
Fluorometric 24-Well Cell Invasion Assay was used (Millipore,
Billerica, MA). Cells from passage numbers 3, 4, and 5 of both
WiT49-GFP-2A-SIX2 and WiT49-GFP were serum-starved (0.2%
FBS) for 18 hours. After harvesting and washing, cell pellets were
resuspended in 1 ml of serum-free medium, counted, and brought to a
volume to give 1 × 106 cells per ml. Invasion assay inserts were handled
with sterile forceps; 300 μl of serum-free DMEM was added to the
interior of each insert and allowed to rehydrate the insert for 15minutes
at room temperature. After rehydration, 250 μl of media was removed
from each insert; 250 μl of a cell suspension containing 1 × 106 cells per
ml in chemoattractant-free media was added to each insert; 500 μl of
media containing 15% FBS was added to the outer chamber. Plates
were covered and incubated for 24 hours at 37°C in a CO2 incubator.
The remaining cell suspension was pipetted out of each insert, and the
invasion chambers were inserted into clean wells containing 225 μl of
cell detachment solution. Invasion chambers were incubated for 30
minutes at 37°C. Cells were dislodged from the underside of the
chamber by tilting during incubation, and inserts were removed from
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1:75 with 4× lysis buffer) were added to each well containing 225 μl of
cell detachment solution with the cells that invaded through the
membrane. The wells were incubated for 15 minutes at room
temperature; 200 μl of the mixture was transferred to a 96-well plate
and read with a fluorescence plate reader using 480/520 nm filter set.
Canonical WNT Signaling
To investigate the effects of SIX2 on canonical WNT pathway
activation, the TOPFlash and FOPFlash (gifts of Ethan Lee, Vanderbilt)
and survivin (gift of Michael Khan, University of Southern California)
reporter plasmids were transfected into the experimental cell line
WiT49-GFP-2A-SIX2 and the control cell line WiT49-GFP [28,31].
Cells were transfected using the X-tremeGENE HP DNA Transfection
Reagent (Roche) following the manufacturer’s protocol. Twenty four
hours after transfection, WNT3a conditioned media was added to
cultures to activate reporter plasmids. The Luciferase Assay System
(Promega) was used to measure WNT signaling activation. Growth
media were removed from the TOPFlash and FOPFlash transfected
cells, and cells were rinsed with PBS; 200 μl of 1× lysis buffer was added
to the cells, and one freeze-thaw cycle was performed to ensure cell lysis.
Cells were scraped from the culture plates and transferred to
microcentrifuge tubes. Tubes were vortexed for 10 seconds and
centrifuged at 12,000g for 2 minutes at 4°C. The supernatant,
containing the cell lysate, was transferred to a new tube, and 20 μl of
cell lysate per sample was added to a 96-well plate; 100 μl of luciferase
assay reagent was added per well, and the light produced was measured
immediately in a SpectraMax spectrophotometer (Molecular Devices).
Real-Time Polymerase Chain Reaction
To evaluate effects of SIX2 on WNT pathway signaling, reverse
transcription was performed with 1 μg of RNA using the RT2 First
Strand cDNA synthesis kit (SA Biosciences, Valencia, CA). The RT2
Profiler PCR arrays specific for the WNT signaling pathway
(PAHS-043YA) was purchased from SA Biosciences and used
according to the manufacturer's instructions [28,32]. Changes in
WNT pathway genes were evaluated on a BioRad iCycler for passages
2, 3, and 4 of each cell line (one plate per passage). This array provides
quantitative analysis of 84 WNT pathway components and target
genes with expression normalized to a panel of five housekeeping
genes on a 96-well plate format.Statistics
Analysis of variance (ANOVA) was used to compare differences in
experimental and control cell lines for colony number and size, WNT
reporter assays, and invasion. Passage effects were not statistically
significant for these assays (all P N .1). However, due to important
interactions observed between group and passage for the proliferation
assay, proliferation was analyzed separately by passage using a two-
way ANOVA for group and time and their interaction. Model-based
least square means were used to compare pairwise group differences,
differences between time points, and group differences by time point,
as warranted, adjusting for multiple comparisons using the Tukey-
Kramer method. Differences in WNT pathway gene expression
between cell lines were evaluated using statistical software available
through the SA Biosciences website and were specific to these
quantitative polymerase chain reaction (PCR) analyses. Statistical
significance for all comparisons was set at P b .05. ANOVA and
Multilevel Multivariate Analysis of Variance (MMANOVA) wereconducted in SAS 9.2. Data were represented graphically using
GraphPad Prism 6 software.
Results
Co-Expression of SIX2 and NCAM Specifies the Multipotent
CM of the Embryonic Kidney
Serial sections of human fetal kidney specimens ranging between
16 and 20 weeks gestation age were probed for SIX2 and NCAM
antigens and showed overlapping yet disparate expression domains of
these two nephron progenitor markers (Figure 1). As expected, both
SIX2 and NCAM co-labeled most robustly the condensed CM,
whereas SIX2 appeared to label the loosely aggregated metanephric
mesenchyme (MM) more diffusely than NCAM, where the latter was
detected minimally if at all. Interestingly, NCAM appeared to label a
larger population of the CM (up to four cell layers) than SIX2, which
was visualized robustly in only one or two cell layers immediately
surrounding the ureteric bud (UB). UB structures were negative for
both antigens. Among the early epithelial structures differentiated
from the CM, NCAM appeared to label through the comma-shaped
body and no further, and SIX2 labeled at most through the pre-
tubular aggregate.Co-Expression of SIX2 and NCAM Principally Labels
Undifferentiated and Proliferating WT Blastema
Of the 41 WT specimens included in the three TMAs, 36 were
primary lesions untreated before resection (4 had been pretreated and
1 was obtained from a metastatic deposit only). Metastatic specimens
accompanied 5 of these 36 (13.9%) primary WTs. Overall, SIX2 was
expressed in 35 (97.2%), and NCAM in 33 (91.7%), of these primary
untreated WTs (Figure 2). Expression of both SIX2 and NCAM
within any cell type (i.e., either blastema or epithelia) was visualized in
29 of the total 36 (80.6%) primary untreated WT specimens.
When evaluating specific cell types for expression of either or both
proteins, blastema was present in 30 of these 36 primary untreatedWT
specimens, and 29 (96.7%) of these undifferentiated cellular
compartments showed highly specific co-expression of SIX2 and
NCAM (Figure 2). Acknowledging that blastema occurred far more
abundantly than epithelia in this cohort of consecutiveWTs, only 11 of
27 (40.7%) specimens having epithelia for evaluation co-expressed both
SIX2 and NCAM within this differentiated cellular compartment.
While NCAM is almost exclusively detected at the cell membrane in
either blastema or epithelia (i.e., its subcellular localization does not
appear to change in WT), unexpectedly, 7 (38.9%) of the 18 primary
untreated WTs having epithelial detection of SIX2 showed cytosolic
compartmentalization, which is an unusual subcellular location for this
transcription factor in either undifferentiated blastema or the multi-
potent CM. In general, SIX2 and NCAM detection using immuno-
peroxidase techniques largely overlapped in the same regions of specific
cell types (i.e., blastema and epithelia) within a given WT; however,
stroma showed no detection of either protein.
Contained within these TMAs were five specimens acquired from
metastatic deposits (lung, liver, nephrectomy bed, and lymph nodes).
All five metastases showed NCAM expression, and four showed SIX2
expression. As expected, neither the malignant (i.e., clear cell
sarcoma) nor the benign (i.e., mesoblastic nephroma) childhood
renal tumors serving as controls showed expression of the SIX2 or
NCAM proteins, suggesting a different cell of origin for these tumor
types other than the CM and its epithelial derivatives.
Figure 1. Immunoperoxidase staining (brown) for SIX2 (A) and NCAM (B) in serial sections of a 20-week gestation human fetal kidney
included in one TMA. (A) SIX2 shows rich nuclear expression in one or two cell layers of the CM (arrow) immediately adjacent to the UB,
which is negative for this protein. The intervening MM shows positive SIX2 expression mixed between the cytosol and nuclear
compartments. (B) In contrast to SIX2, NCAM is detected exclusively in the CMbut in two ormore cell layers and is also negative in the UB.
All images are captured at 400× (bar = 50 μm). The sectioning artifact in both serial sections should be regarded as non-specific staining.
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these WT specimens, immunostaining for the proliferation marker,
PCNA, was performed on a third serial section as well (Figure 2).
WTs are notoriously proliferative cancers, and as expected, PCNA
was visualized in a highly specific and diffuse pattern within these WT
specimens; although the clear cell sarcoma specimen showed
detection of PCNA, the mesoblastic nephroma benign control
tumor was entirely devoid of this proliferation marker. As depicted,
PCNA showed an expression domain that closely paralleled both
proteins but subtly appeared to associate more with SIX2 (Figure 2).
The conclusion of these extensive IHC experiments is that regions of
highly proliferative blastema (and epithelia more rarely) express both
NCAM and SIX2 robustly and that SIX2 more specifically labels
individual proliferating cells.
Overall, from this IHC analysis of the three TMAs, cellular
regions within each WT punch composed of a specific cell type
(e.g., blastema or epithelia) often expressed both SIX2 and NCAM,
although individual cells within these regions appeared to express
variably both, one or the other protein. To examine the cellular and
subcellular co-expression domains of SIX2 and NCAM more closely
in WT, we performed co-immunofluorescence of additional WT
specimens not included in the TMAs. As shown, co-expression of
SIX2 (green) and NCAM (red) in a clinical WT specimen labels a
population of loosely aggregated blastema that appears furthest from
the more differentiated elements (DAPI blue only) in various zones of
epithelial transition (Figure 3). Analogous to compartmentalization
observed within the CM of the embryonic kidney, in which
progenitor cells are coursing through the mesenchymal-to-epithelial
transition, a spatial gradient in degree of differentiation also appears in
this malignant context, passing from the most undifferentiated cell
type, SIX2+/NCAM+, to the most differentiated, i.e., SIX2−/
NCAM− (DAPI only), with an intermediate cell type SIX2−/
NCAM+ existing between these cellular compartments. Lending
further evidence that co-expression of SIX2 and NCAM designate a
blastema population likely containing the WT cancer stem cell, serial
sections of WT show tight blastemal co-detection of NCAM and
CITED1, as we have shown previously that the latter transcriptional
regulator is a marker of proliferating WT cells and overlaps
considerably, but not exclusively, with the SIX2 expression domain
in WT (Figure 4) [20,28].SIX2 Overexpression in a WT Cell Line—Model Validation
To mimic the clinically observed overexpression of SIX2 inWT and
to test its biologic effects and mechanism of action, we engineered a
model using the humanWT cell line,WiT49, which forms as wild-type
cells predominantly differentiated (stromal and epithelial compartments
with rare differentiating blastema) xenograft tumors and is a low
expresser of SIX2 (e.g., detected by PCR only) [28,33]. After
transfection of WiT49 cells with either the control (vGFP only) or
experimental (vGFP-2A-SIX2) plasmids in our model, stable integra-
tion of each transgene was achieved within 5 weeks of neomycin
pressure selection. To enrich each cell line for high expression of the
plasmid, as determined from intensity of vGFP detection, viable cells
were sorted according to fluorescent signal, and high expressers were
collected for expansion in culture (Figure 5, A and B). Using this
approach, the percent of vGFP-positive cells for both cell lines increased
from 80% at baseline to nearly 100%.
To validate the model, direct fluorescence microscopy of cells
in vitro showed rich visualization of predominantly nuclear vGFP
signal in both cell lines (Figure 5, C and D). To ensure that the vGFP
marker and SIX2 were indeed liberated from one another by inserting
the intervening 2A cleavage peptide, Western blot analysis of protein
collected from multiple passages (2-4) of each cell line showed that
both vGFP and SIX2 traveled at the standard weights (Figure 5).
SIX2 Effects on WiT49 Biology
Having validated this model as continually overexpressing SIX2
across multiple passages ofWiT49 cells (p5) and without the potential
for physical constraints of a large epitope tagged onto this transcription
factor, we next proceeded to test the effects of persistent SIX2
activation on WT cell survival, given its established role in the
maintenance of, and repression ofWNT-dependent differentiation in,
the CM of the embryonic kidney. Using our established protocol for
anchorage-independent growth in soft agar, we evaluated the effects of
SIX2 overexpression on WiT49 cell survival (Figure 6, A–D). SIX2-
overexpressing cells showed a significantly greater colony count
(median count, 3429; interquartile range: 540-9704) than vGFP
control cells (median 160; interquartile range: 150-186; P = .027;
Figure 6). Colony diameter was also significantly greater for SIX2-
overexpressing cells relative to controls (median diameter 90.8 vs 67.6,
respectively; P = .0009; Figure 6).
Figure 2. Representative images of immunoperoxidase staining (brown) for SIX2, NCAM, and the proliferation marker PCNA as captured
from serial sections of the three TMAs. (A–C) A blastemal predominant but triphasic favorable histology WT (WT1-FH) shows the typical
expression domain for each protein. Note that significant regions also show overlapping expression yet discrete individual areas of
detection. Arrowheads show a pocket of epithelia (blue only) that do not express either SIX2 or NCAM but are proliferative. The
intervening stroma (white regions) does not express any of these three proteins. (D–F) A second FH WT (WT2-FH) that is blastemal
predominant shows a similar expression domain for each protein. Note again that the stroma is negative and that PCNA staining more
closely parallels SIX2 than NCAM. Punch images are captured at 100× (bar = 200 μm). (G–I) A third FH WT (WT3-FH) also shows
overlapping yet unique expression domain for each protein. Intervening stroma again is negative. Images are captured at 400× (bar = 50
μm). (J–L) Low and (M–O) high powered images (scales as above) of a metastatic deposit in a lymph node (LN) obtained from a fourth FH
WT (WT4-FH). Note that themetastaticWT cells are strongly positive for each protein without significant variability in expression domains.
(P–R) For comparison, expression patterns of these three proteins are provided within an unfavorable histology WT (WT5-UH) specimen
(400×; bar = 50 μm). As with the FH specimens above, considerable overlap, yet with areas of distinctive expression domains, was
observed again. However, it appeared that SIX2 more closely paralleled the expression pattern of PCNA. Stroma remained negative for
these three proteins in the UH context.
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cells as another in vitro measure of enhanced cell survival. Using our
established model of WiT49 proliferation, we detected an overalltrend that SIX2 enhanced proliferation and separated from controls
over time, although statistical significance was not met when
comparing all passages together (Figure 6). However, the effect of
Figure 3. (A and B) Immunofluorescent co-localization of SIX2 (green)
and NCAM (red) in two distinct “zones of differentiation”within an FH
WT specimen. The loosely aggregated and most undifferentiated
blastema stains positively for both SIX2 and NCAM, although this
region also contains more rare SIX2+/NCAM− cells. As cells move
toward themore differentiated epithelial state (SIX2−/NCAM−/DAPI+;
blue only) showing tubule formation, the intermediate group of
aggregating cells is SIX2−/NCAM+ (red only). Although not absolute,
the majority of differentiating or differentiated WT cells appear to lose
SIX2 expression, as shown in these two images (400×).
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point evaluated (e.g., 72 hours vs 24 hours, P = .047) and passage
number after transfection, as early passage achieved the highest statistical
significance between cell lines (passage 2; P b .0001; Figure 6). In later
passages, SIX2 continued to show the same enhanced proliferative
response in WiT49 cells across the three time points evaluated (as in
earlier passages), although the control cells in later passages also showed
an increased proliferative response, which mitigated statistically
significant differences between cell lines when all passages were
analyzed together.
Regarding SIX2 effects on invasiveness of WiT49 cells, we had an
insufficient number of observations to conclude firmly any change in
this biologic parameter, although a tendency toward repression was
detected (data not shown).SIX2 Effects on Canonical WNT Pathway Reporter Assays
Because SIX2 is known to regulate self-renewal of nephron
progenitors and to counterbalance WNT-dependent differentiation
signals in the CM, we next sought to clarify its effects on canonical
WNT signaling in the WT context. First, to gain perspective in the
embryonic context, using our previously published model on WNT
signaling in HEK-293 cells that have been stably transfected with a
TOPFlash reporter, we evaluated the effects of transiently overex-
pressing SIX2 in this immortalized but non-malignant cell line [28].
In HEK-293 cells, we observed that SIX2 had no effect on global
canonical WNT signaling when testing the TCF/LEF-dependent
TOPFlash reporter assay (Figure 7A). Interestingly, when this
reporter was transfected into the two WiT49 cell lines, we observed
across 11 biologic replicates a consistent effect of SIX2 to repress
canonical WNT signaling, although variability in the magnitude of
repression between experiments mitigated statistical significance
when comparing mean values between groups (Figure 7B).
Specifically, 8 of the 11 (72.7%) biologic replicates tested showed
that SIX2 overexpression repressed TOPFlash activation in WiT49
cells. The variability in absolute magnitude of TOPFlash activation is
likely explained by variations in concentration of WNT3a collected
from supernatant of transfected production cells and used to activate
the reporter between different experiments (a standard technique to
generate WNT proteins for TOPFlash assays). Taken together, these
observations using a TOPFlash reporter assay likely reflect a balanced
effect in the embryonic context of SIX2 to repress differentiation and
to activate stem cell survival through interactions with specific
components of the canonical WNT pathway but that becomes
deregulated and unbalanced in malignancy.
Because canonical WNT signaling operates through β-catenin
interaction with either CBP, leading to maintenance of stemness, or
p300, resulting in commitment to epithelial differentiation, we sought
next to distinguish what effect SIX2 has on the former pro-stem
pathway and if this transcription factor tips the balance toward a cell
survival pathway in the malignant context. To test SIX2 effects on
CBP/β-catenin–dependent signaling, we transfected a survivin report-
er, which is activated specifically through the interaction of β-catenin
with CBP, into the two WiT49 cells lines established in this model.
Interestingly, SIX2 was observed to enhance significantly survivin-
dependent signaling in the WT context (P = .034; Figure 7C).
Although we are unaware of a reporter assay that is specific to β-catenin
interaction with p300, we suspect that the relative balance observed
with the TOPFlash reporter potentially originates from repression of
this differentiation pathway, given the observed up-regulation of the
pro-stem CBP/β-catenin signaling.
SIX2 Effects on WNT Gene Expression in WiT49 Cells
Because we detected differential effects of SIX2 on canonical WNT
signaling, we questioned next what WNT pathway interactors would
be altered in this WT model across three passages (i.e., biologic
replicates). Using quantitative PCR to analyze expression changes in
84 WNT pathway genes having known functions, we detected
statistically significant effects of SIX2 on 35 genes (41.7%), 31
(36.9%) of which were repressed (Table 1).Discussion
This study showed foremost that SIX2 overexpression in a human
WT cell line confers a survival predisposition to this embryonal tumor
of childhood analogous to its documented functions in the developing
Figure 4. Serial sections of a human WT specimen immunostained for NCAM and CITED1 (B and D appear rotated 90° counterclockwise
relative to A and C because of orientation from tissue sectioning). (A and B) Low power photomicrographs of a WT specimen
immunostained for NCAM and CITED1, respectively (100×; bar = 200 μm). The blastemal compartments show nearly exact overlap in
detection of both antigens with differences only appearing in the more mature tubular elements (arrowhead) that do not express NCAM
but variably express CITED1. (C and D) High power photomicrographs (400×; bar = 50 μm) show differences in subcellular compartment
detection of both antigens but also the tight overlap between blastemal detection.
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β-catenin interaction preferentially with the co-activator, CBP, which
is a recognized mechanism of stem cells, whether normal or
malignant, to maintain self-renewal and is currently being evaluated
as a therapeutic target of PRI-724 in several adult solid cancers.
We found in previous studies that SIX2 is expressed aberrantly
across a broad spectrum of WTs and is principally a marker of
undifferentiated blastema, its putative cancer stem cell, yet an
understanding of its functional significance in the malignant context
until now has remained an extrapolation from development [20,21].
Importantly, in the embryonic kidney, SIX2 has been established as a
critical regulator and self-renewal mechanism of the nephron
progenitor pool within the CM [9–11,19]. As a result of those
prior studies, we postulated that SIX2 likely would be hijacked for a
similar gain of perpetuity in the WT context, albeit in an unchecked
manner. Indeed, using a validated model of SIX2 overexpression in a
WT cell line, we have observed significantly enhanced cell survival in
soft agar and an early effect to increase cell proliferation, consistent
with a previous report [22].
In the developing kidney, significant “cross-talk” occurs between
the UB structures, which will form the collecting tubules of the distal
nephron, and the condensing MM (or the CM), which will form the
epithelial elements of the proximal nephron, including glomeruli
[34]. To establish proper nephron endowment of the fully developed
and mature kidney, this “cross-talk” must be tightly regulated and
coordinated between the UB and the CM, which together direct
reciprocal interactions that lead to growth and development of the
progenitor pool and committed epithelial structures. Asymmetric celldivision is at the cornerstone of this coordinated maintenance to
spawn an equal balance of both stem and epithelial-committed
daughter cells. Indeed, in the murine embryonic kidney,
Wnt9b, secreted from the UB, has been shown to target SIX2 as a
mechanism to induce epithelial conversion [11]. Furthermore, SIX2
and β-catenin have been shown to share gene regulatory networks in
the embryonic kidney, providing additional evidence that these two
transcriptional regulators tightly coordinate the mesenchymal-to-
epithelial transition of the CM [19]. By evaluating differentially two
canonical WNT pathway reporter assays in our WT model, it appears
that SIX2 may direct β-catenin away from interaction with p300,
which induces epithelial commitment within stem cells, and toward
interaction with CBP that drives progenitor maintenance. Any
imbalance in this tightly coordinated binary branch point for WNT-
dependent cell fate decisions could result in symmetric cell division,
whereby both daughter cells remain in a stem state. Effectively, in the
malignant context of WT, SIX2 may promote β-catenin interaction
with CBP, fueling perpetuity of a WT stem cell. Interestingly, in this
current WT model, SIX2 was found to repress significantly an
abundance of WNT pathway genes that could collectively shift the
balance to maintaining a perpetual loop for WT survival, although
admittedly our studies were not designed to test the effects on WT
biology of each of these altered WNT genes.
Much emphasis in cancer biology has been directed recently
toward defining the biologic properties of the mysterious cancer stem
cell [35,36]. Embryonal tumors of childhood by definition arise from
rogue progenitor cells that somehow escape terminal differentiation
and retain the hallmark feature of a “small round blue” cell having a
Figure 5.Model validation studies in the human WT cell line, WiT49. (A and B) Results of FACS for viability and high expression of vGFP.
(A) Control cell line: vGFP only. (B) Experimental cell line expressing vGFP-2A-SIX2 transgene. (C and D) Direct immunofluorescence of the
two cell lines shows high vGFP detection in the nucleus and weak vGFP detection in the cytosol. (E) Western blot to confirm transgene
expression and protein translation in the two cell lines. SIX2 is detected at its appropriate weight in a positive-control clinical WT specimen
and in three consecutive passages of the WiT49-vGFP-2A-SIX2 cell line (expression continues similarly to passage 6—data not shown).
Importantly, SIX2 protein is not detected in wild-type WiT49 cells nor in the control vGFP-only cells. vGFP was detected in all transfected
cells but importantly not in the clinical WT specimen or wild-type WiT49 cells. β-Actin loading controls are shown for each Western blot.
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Figure 6. SIX2 effects on WiT49 cell survival. (A and B) Images captured from a representative soft agar well showing grossly differences
in colony number and size between control and experimental cell lines. (C) Colony count was significantly increased for WiT49 cells
transfected with the vGFP-2A-SIX2 transgene (interquartile box shown, with median bar and mean + sign). (D) Colony size was also
greater in the SIX2-expressing WiT49 cells. (E) Although SIX2-expressing cells appeared to have enhanced proliferative response when
analyzing all passages and time points simultaneously, an insufficient number of observations were performed to conclude statistically
significant differences. However, when separating out individual passages, early passages of SIX2-expressing WiT49 cells were noted to
be significantly more proliferative than vGFP-only cells (F). This effect of SIX2 persisted although statistical significance was mitigated as
control cells became more proliferative in later passages too; 72-hour time points showed significantly more proliferative cells than
24-hour time points.
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that NCAM, a critical cell surface marker of a putative WT stem cell,
largely associates with expression of SIX2 in clinical specimens
[23,24,26]. Curiously, although SIX2 and NCAM appear to be co-
expressed in a majority of individual blastema, and more rarely in a
minority of epithelia, other cells within these two compartments
express one or the other protein, but not both. The functional
significance of these different expression patterns remains unclear,
although we expect on the basis of our observations that co-expression
of SIX2 and NCAM labels a less differentiatedWT cell, likely one that
is fixed in a perpetual loop of self-renewal and maintaining stemness.
We acknowledge several limitations of this study. First, we have
evaluated only WiT49 cells showing high expression of vGFP as asurrogate for SIX2, given that the transgene we designed included a
cleavage peptide and should yield equal protein translation (i.e., if
vGFP detection is high then so should be SIX2). Importantly,
however, a dose effect of SIX2 overexpression on WT biology was not
evaluated in this model, as low vGFP-emitting cells were not collected
for culture expansion, and the reason being that, within clinical WT
specimens, blastema (and rarely epithelia) appears typically to express
a consistent and strong content of SIX2. Second, we have evaluated
the effects of SIX2 overexpression in only a single WT cell line, as no
others are commercially available at the present time, and those
primary WT lines that our laboratory has initiated have not yet been
validated as tumorigenic in a xenograft model. Third, comparison of
biologic effects between SIX2 and control plasmid was only
Figure 7. SIX2 effects on canonical WNT reporter assay activation. (A) TOPFlash activation in HEK-293 cells stably transfected with this
reporter plasmid. Baseline control HEK-293 cells having the TOPFlash reporter but not transfected with either vGFP or vGFP-2A-SIX2
plasmid and not stimulated with WNT3a (L) show low activation. When transfected with either control or SIX2 plasmid, and stimulated
with WNT3a, canonical WNT activation appears balanced. (B) After transfection of the TOPFlash reporter into the respective model cell
lines, an insufficient number of observations were made to conclude statistically significant differences, although 8 of 11 (72.7%)
experiments showed repression of reporter activation versus 3 of 11 (27.3%) that showed enhanced activation. (C) To examine whether
SIX2 promoted enhancedWiT49 cell survival through CBP/β-catenin–dependent interaction, a survivin reporter assay was transfected into
the model cell lines. Notably, SIX2 significantly enhanced canonical WNT pathway activation through the survivin promoter, which
represents a pathway to maintain stemness and cell survival.
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test differential effects in the embryonic context (e.g., HEK-293 cells)
beyond the TOPFlash reporter assay. We only evaluated overexpres-
sion of SIX2 and the control plasmid in this embryonic kidney cell
line to establish baseline context of WNT/β-catenin signaling and toTable 1. SIX2 Effects on WNT Pathway Gene Expression.
Symbol Fold Regulation P Value
MT1A 23.464 .02682
CCND2 7.057 .000623
WNT1 1.8909 .040953
CXADR 1.7642 .04628
BTRC −1.1336 .043991
RUVBL1 −1.3022 .010522
GSK3B −1.3326 .031276
CTNNB1 −1.4283 .016683
CTNNBIP1 −1.4958 .024324
DVL1 −1.4958 .020268
DVL2 −1.5308 .03886
CSNK1A1 −1.7183 .006969
FBXW11 −1.7183 .001276
VANGL2 −1.7183 .023559
PITX2 −1.7584 .007196
AXIN2 −1.7995 .045722
PRICKLE1 −1.8846 .008141
CALM1 −1.8846 .000792
LEF1 −2.1154 .014944
CTBP1 −2.1649 .005634
WNT3 −2.2673 .013814
DAB2 −2.5449 .004921
SFRP4 −2.6653 .040353
FZD9 −2.7276 .015464
WNT6 −2.8566 .016166
WISP1 −2.9233 .037553
NFATC1 −3.2813 .025631
SKP2 −3.358 .000671
WNT11 −3.4365 .004348
WNT9A −3.5991 .010208
KREMEN1 −3.8574 .001497
CYP4V2 −4.0398 .005576
SFRP1 −4.9736 .000086
DKK1 −7.1981 .022828
NKD1 −325.7498 .002323reveal more clearly whether deregulated pathway activation in the
experimentally manipulated WiT49 cells occurred. Fourth, although
we observed a consistent effect of SIX2 to repress TOPFlash
activation across the majority of multiple experiments, statistical
significance was not achieved when comparing mean values between
cell lines given the variability in magnitude of activation between
observations. Nevertheless, we believe that this repressive effect is real
and that the variability is explained by differences in WNT3a
concentration used between experiments, which is challenging to
measure when generating this activating protein from transfected cell
cultures. Finally, our studies were not designed to determine whether
SIX2 is a driver or passenger in WT survival, which is the focus of
ongoing studies.
In summary, we developed and validated an in vitromodel of SIX2
overexpression in a human WT cell line to mimic observations of its
expression domain in clinical specimens and to test SIX2 effects on
WT biology. It appears from these studies that SIX2, especially when
co-expressed with NCAM, labels the putative WT stem cell in clinical
specimens and promotes WT cell survival in this model. Our studies
introduce an early clue to the mechanism through which
SIX2 operates as a means to confer WT cell survival by activating
survivin-dependent signaling, a path that requires β-catenin interac-
tion with the CBP co-activator. Future studies are warranted to
dissect further the mechanism as to how deregulated SIX2 activity
shifts the balance of WNT/β-catenin signaling toward symmetrical
maintenance of a WT stem cell. Such work will likely reveal a
targetable mechanism in WT stem cell perpetuity that is currently
being evaluated in various adult solid tumors.
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